Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Retained Earnings (2017 - 2025)

Crinetics Pharmaceuticals has reported Retained Earnings over the past 9 years, most recently at -$1.4 billion for Q4 2025.

  • Quarterly results put Retained Earnings at -$1.4 billion for Q4 2025, down 48.87% from a year ago — trailing twelve months through Dec 2025 was -$1.4 billion (down 48.87% YoY), and the annual figure for FY2025 was -$1.4 billion, down 48.87%.
  • Retained Earnings for Q4 2025 was -$1.4 billion at Crinetics Pharmaceuticals, down from -$1.3 billion in the prior quarter.
  • Over the last five years, Retained Earnings for CRNX hit a ceiling of $1.6 million in Q2 2025 and a floor of -$1.4 billion in Q4 2025.
  • Median Retained Earnings over the past 5 years was -$245.9 million (2021), compared with a mean of -$400.1 million.
  • Biggest five-year swings in Retained Earnings: tumbled 3284750.0% in 2022 and later surged 953.16% in 2025.
  • Crinetics Pharmaceuticals' Retained Earnings stood at -$275.3 million in 2021, then surged by 98.57% to -$3.9 million in 2022, then skyrocketed by 124.85% to $977000.0 in 2023, then crashed by 97552.41% to -$952.1 million in 2024, then plummeted by 48.87% to -$1.4 billion in 2025.
  • The last three reported values for Retained Earnings were -$1.4 billion (Q4 2025), -$1.3 billion (Q3 2025), and $1.6 million (Q2 2025) per Business Quant data.